TMEM11 and Miyoshi myopathy: PS2 supporting (one proven de novo occurrence), PS3 strong (well‐established functional studies supportive of a damaging effect), PS4 supporting (one proband meeting FPD‐MM phenotype), PM1 moderate (located in mutational hotspot), PM2 (absent from controls), PP3 supporting (computational evidence supports deleterious effect)